Therapy of venous hypertension in calves with total artificial heart (TAH)
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu srovnávací studie, časopisecké články
PubMed
2656540
Knihovny.cz E-zdroje
- MeSH
- antihypertenziva terapeutické užití MeSH
- centrální žilní tlak * účinky léků MeSH
- clonidin terapeutické užití MeSH
- hypertenze terapie MeSH
- jaterní testy MeSH
- kaptopril terapeutické užití MeSH
- kardiostimulace umělá * MeSH
- methyldopa terapeutické užití MeSH
- nifedipin terapeutické užití MeSH
- pooperační komplikace terapie MeSH
- prazosin terapeutické užití MeSH
- skot MeSH
- umělé srdce * MeSH
- zvířata MeSH
- Check Tag
- skot MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- srovnávací studie MeSH
- Názvy látek
- antihypertenziva MeSH
- clonidin MeSH
- kaptopril MeSH
- methyldopa MeSH
- nifedipin MeSH
- prazosin MeSH
Vasomotor disregulation, preponderantly expressed by a pathological increase of central venous pressure (CVP) in calves with total artificial heart (TAH), starts to be evident from about the 50th day of pumping. The main cause of this state is an imbalance in cardiac receptor areas. Ventricular vasodepressor mechanisms are eliminated with the ventricular tissue, which is replaced by the artificial blood pump. In the stumps of both atria, which remain in situ, all neural elements disappear immediately after TAH implantation, but within two months they are fully regenerated. Regenerated atrial receptors are the starting points of afferent neural stimuli, which in the vasomotor center of the brainstem, increase the activity of the vasoconstricting functional component. A general tendency to vasoconstriction, now not well counterbalanced, increases, and the progressive venous hypertension causes loss of liver function and morphology. Two therapeutic approaches were tried: afferent therapy by atrial electrical stimulation, and efferent therapy by the administration of antihypertensives. Both kinds of this therapy were sufficiently effective in reducing CVP, protecting the liver, and prolonging average survival.